Triveni Bio Initiates Phase 2 Trial of TRIV-509 for Atopic Dermatitis Treatment Triveni Bio has begun a crucial Phase 2 clinical trial for TRIV-509, targeting atopic dermatitis, showcasing advancements in antibody treatments.

Triveni Bio Initiates Phase 2 Trial of TRIV-509 for Atopic Dermatitis Treatment #USA #Atopic_Dermatitis #Watertown #Triveni_Bio #TRIV-509

Triveni Bio Commences First Phase 1 Trial for Atopic Dermatitis Treatment Triveni Bio announces the start of its Phase 1 clinical trial for TRIV-509, a promising treatment for atopic dermatitis, highlighting the importance of kallikreins.

Triveni Bio Commences First Phase 1 Trial for Atopic Dermatitis Treatment #USA #Watertown #Triveni_Bio #KLK5 #TRIV-509